Novo Nordisk Discontinues Velosulin® BR
Velosulin® BR was discontinued in the U.S. as of November 3, 2003. In the U.S., Novo Nordisk is notifying healthcare providers so they may be in contact with their patients and can work together on a transition to another therapy. In addition, the are notifying patients enrolled in the Keeping Well With Diabetes program who use Velosulin BR. The Novo Nordisk call center (1-800-727-6500) is available to answer questions from patients and healthcare providers.
The use of Velosulin has been in decline for many years. At present, less than 0.1% of people requiring insulin in the United States use Velosulin. Velosulin® BR was initially designed for continuous subcutaneous insulin infusion patients who were using regular human insulin in an insulin pump. Novo Nordisk® is the manufacturer of NovoLog® (insulin aspart [rDNA origin] injection), the only other insulin product approved by the FDA for subcutaneous insulin infusion via an external insulin pump. The discontinuation of Velosulin will provide Novo Nordisk with greater production capacity to meet the increasing demand for our new and innovative diabetes product offerings.
Any change in insulin therapy should be made cautiously and under medical supervision. Full prescribing information for NovoLog is available by at www.novonordisk-us.com or by calling 1-800-727-6500.
Source: E-mail from Novo Nordisk Corporate Communications
November 16, 2003
|Return to the Top of This Page|
Last Updated: Thursday February 27, 2014 19:28:21
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.